Answer
If a systemic hypersensitivity reaction, immediate or delayed, occurs during tralokinumab treatment, administration should be discontinued and appropriate therapy initiated.
Sources for this answer
- Adtralza 150 mg solution for injection in pre-filled syringeLeo Laboratories Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 9Document updated
Sources checked